CompanyGraph
CSPC Pharmaceutical Group Ltd.
1093 · HKEX · China
Price data from its CVG listing on XSTU, quoted in EUR
cspc.com.hkFinancials as of FY2025
At a glance
- Depends onDownstream position: depends on 11 industries, supplies 6
- ScaleMarket cap is $11.52B, above the global median of $1.18B
- FinancialsAltman Z-Score 5.76: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
3.45%Above 5Y avg (3.33%)
Annual Rate
HKD 0.30Paid semi-annual
Payout Ratio
64.8%Moderate
Payback Period
3.3 yr
Last Ex-Dividend
Jun 24, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
90.35BHKD11.52B · vs all stocks (USD)
Trailing P/E
21.89xRevenue (TTM)
29.63BCNY3.78B · vs all stocks (USD)
Profit Margin
12.82%Beta
0.7540xvs all stocks
52-Week Change
-16.09%vs all stocks
Forward Annual Dividend Yield
3.45%vs all stocks
Market Capitalization
90.35BHKD11.52B · vs all stocks (USD)
Enterprise Value
106.46BHKD13.57B · vs all stocks (USD)
Trailing P/E
21.89xForward P/E
12.82xPrice to Sales (TTM)
3.92xPrice to Book (MRQ)
2.59xEnterprise to Revenue
3.59xEnterprise to EBITDA
19.95xProfit Margin
12.82%Operating Margin
15.06%Return on Assets (TTM)
8.31%Return on Equity (TTM)
9.56%Revenue (TTM)
29.63BCNY3.78B · vs all stocks (USD)
Revenue per Share (TTM)
2.23CNYUpdated Aug 19, 2026Quarterly Revenue Growth
-7.80%Gross Profit (TTM)
19.34BCNY2.47B · vs all stocks (USD)
EBITDA (TTM)
5.94BCNY757.35M · vs all stocks (USD)
Net Income (TTM)
3.80BCNY484.27M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-41.80%Operating Cash Flow (TTM)
5.83BCNY743.48M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
3.88BCNY494.93M · vs all stocks (USD)
Forward Annual Dividend Rate
0.3000HKDUpdated Aug 19, 2026Forward Annual Dividend Yield
3.45%vs all stocks
Trailing Annual Dividend Rate
0.2900HKDUpdated Aug 19, 2026Trailing Annual Dividend Yield
3.34%vs all stocks
5-Year Average Dividend Yield
3.33%vs all stocks
Payout Ratio
64.75%Minority Interest (Equity)
1.37BCNYFY2025 · Dec 31, 2025Revenue
26.01BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
8.95BCNYFY2025 · Dec 31, 2025Gross Profit
17.06BCNYFY2025 · Dec 31, 2025Operating Income
4.18BCNY620.09M · vs all stocks (USD)
Pre-tax Income
4.81BCNYFY2025 · Dec 31, 2025Income Tax Expense
931.73MCNYFY2025 · Dec 31, 2025Net Income
3.88BCNYFY2025 · Dec 31, 2025EBIT
4.85BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
5.94BCNYFY2025 · Dec 31, 2025Research & Development
5.81BCNYFY2025 · Dec 31, 2025Selling, General & Administrative
7.29BCNYFY2025 · Dec 31, 2025Other Operating Expenses
-9.97MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
195.87MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
38.59MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.3398CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.3398CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
11.42BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
11.42BSharesFY2025 · Dec 31, 2025Minority Interests (P&L)
5.72MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
5.99BCNYFY2025 · Dec 31, 2025Free Cash Flow
4.03BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
5.25BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
4.81BCNYFY2025 · Dec 31, 2025Stock-based Compensation
-65.95MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-367.58MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
211.57MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
1.41BCNYFY2025 · Dec 31, 2025Capital Expenditures
-1.96BCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-320.25MCNYFY2025 · Dec 31, 2025Net Acquisitions
-29.00MCNYFY2025 · Dec 31, 2025Purchase of Investments
-5.26BCNYFY2025 · Dec 31, 2025Sale of Investments
3.21BCNYFY2025 · Dec 31, 2025Other Investing Activity
258.96MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-3.78BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-28.00MCNYFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-7.00MCNYFY2025 · Dec 31, 2025Common Stock Repurchase
-277.63MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-2.50BCNYFY2025 · Dec 31, 2025Other Financing Charges
445.02MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-2.48BCNYFY2025 · Dec 31, 2025Shares Outstanding
11.41BSharesUpdated Aug 19, 2026Float Shares
7.63BSharesUpdated Aug 19, 2026% Held by Insiders
32.58%vs all stocks
% Held by Institutions
34.94%vs all stocks
Total Cash (MRQ)
12.07BCNY1.54B · vs all stocks (USD)
Total Cash per Share (MRQ)
0.9100CNYUpdated Aug 19, 2026Total Debt (MRQ)
746.11MCNY95.12M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0186xCurrent Ratio (MRQ)
2.19xBook Value per Share (MRQ)
3.38CNYUpdated Aug 19, 2026Total Assets
46.70BCNY6.93B · vs all stocks (USD)
Total Current Assets
22.25BCNYFY2025 · Dec 31, 2025Total Liabilities
12.15BCNYFY2025 · Dec 31, 2025Total Non-current Assets
24.45BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.97BCNYFY2025 · Dec 31, 2025Total Current Liabilities
10.18BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
6.09BCNYFY2025 · Dec 31, 2025Other Short-term Investments
2.78BCNYFY2025 · Dec 31, 2025Accounts Receivable
4.78BCNYFY2025 · Dec 31, 2025Inventory
3.09BCNYFY2025 · Dec 31, 2025Accounts Payable
2.98BCNYFY2025 · Dec 31, 2025Short-term Debt
460.42MCNYFY2025 · Dec 31, 2025Long-term Debt
180.69MCNYFY2025 · Dec 31, 2025Common Stock (Book)
11.06BCNYFY2025 · Dec 31, 2025Retained Earnings
24.48BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
34.55BCNY5.12B · vs all stocks (USD)
Treasury Stock
752.85MCNYFY2025 · Dec 31, 202552-Week Low
6.53HKDUpdated Aug 19, 202652-Week High
11.63HKDUpdated Aug 19, 202652-Week Change
-16.09%vs all stocks
Beta
0.7540xvs all stocks
50-Day MA
7.89HKDUpdated Aug 19, 2026200-Day MA
8.51HKDUpdated Aug 19, 2026Avg 10-Day Volume
68.56MSharesUpdated Aug 19, 2026Avg 30-Day Volume
86.49MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
0.4000CNYUpdated Aug 19, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 5.76: safe zoneNotable
Altman Z-Score: 5.76
Supply Chain
Downstream position: depends on 11 industries, supplies 6Notable
Outgoing: 6.00Incoming: 11.00
High connectivity hub: 17 industry connectionsNotable
Total Connections: 17.00
Scale
Market cap is $11.52B, above the global median of $1.18BNotable
Market cap (USD): 11,518,924,617.068Global Median: 1,179,398,897.704
Revenue is $3.78B, above the global median of $534.05MNotable
Revenue (USD): 3,777,004,154.762Global Median: 534,052,387.958
Levered free cash flow is $494.93M, above the global median of $19.23MNotable
Levered free cash flow (USD): 494,929,948.92Global Median: 19,234,564.734
Companies that share the same coordination system — how they create, deliver, or capture value.
Summit Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Recordati Industria Chimica e Farmaceutica S.p.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Haisco Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Globus Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Cipla Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cytokinetics, Incorporated
Tier 1ProductionApproval-Gated PipelineRuleRisk
Halozyme Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sichuan Kelun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Axsome Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Timee Inc.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
PetroTal Corp
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Qualys, Inc.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities